实验性乙肝治疗评估中现有与新型终点的应用
综述讨论评估实验性乙型肝炎治疗疗效的现有终点与潜在新型终点。HBV功能治愈定义为持续HBsAg丢失和抗-HBs出现,伴停药后血清转氨酶正常化;病毒学或完全治愈还包括HBV cccDNA丢失。现有终点不足以评估许多新疗法,需改进现有病毒学终点用法或开发全新生物标志物。
要点
- HBV功能治愈为持续HBsAg丢失、抗-HBs出现且停药后转氨酶正常。
- 病毒学或完全治愈额外包括HBV cccDNA丢失。
- 现有终点不足以评估新疗法,需新终点或生物标志物。
核心结论
- 现有治疗终点不足以评估许多新型HBV疗法的疗效,需改进现有病毒学终点的使用方式或开发全新生物标志物。
研究设计与样本
- 综述,讨论当前使用的终点、潜在新终点及评估HBV治疗实现功能性和病毒学治愈所需的新标志物。
主要发现
- HBV功能治愈为持续HBsAg丢失和抗-HBs出现,伴停药后血清转氨酶正常化。
- 病毒学或完全治愈额外包括HBV cccDNA丢失。
关键数值与推荐
- HBV功能治愈:持续HBsAg丢失、抗-HBs出现、停药后血清转氨酶正常化。
- 病毒学或完全治愈:在功能治愈基础上还包括HBV cccDNA丢失。
临床怎么用
- 评估新型HBV疗法时需考虑现有终点局限性,并关注不同HBV感染阶段患者选择对药物选择的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
New hepatitis B virus (HBV) therapies are expected to have breakthrough benefit for patients. HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalization of serum aminotransferases off therapy. Virologic or complete cure additionally includes loss of HBV covalently closed circular DNA. Currently available endpoints of therapy are inadequate to evaluate the efficacy of many of the new therapeutics. Therefore, either new ways of using the existing virologic endpoints and laboratory values or entirely new biomarkers are needed. In this review, we discuss the currently used endpoints, potential new endpoints, as well as what new markers are needed to assess the ability of HBV therapeutics to achieve functional and virologic cure in various phases of HBV infection. In addition, we discuss how patient selection from differing phases of HBV impacts the choice of HBV drug(s) needed to achieve cure.
引用
- Block TM, Locarnini S, McMahon BJ, et al. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. Clin Infect Dis. 2017. PMID: 28200098. doi:10.1093/cid/cix129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。